Introduction {#s1}
============

Human somatic cells such as skin fibroblasts can be directly converted into cultures of functional induced neurons (iNs) by the overexpression of pro-neuronal transcription factors ([@bib31]; [@bib7]). As opposed to induced pluripotent stem cell (iPSC) reprogramming and differentiation, direct iN conversion bypasses the pluripotent stage as well as any other stem cell-like stages and preserves epigenetic information of their donor's age, making it a particularly valuable tool to study aging and aging-related disorders ([@bib26]; [@bib48]; [@bib42]). iN technology has also shown promise in vivo as a strategy to replace damaged cells following brain injury by direct conversion of non-neuronal cell types into neurons directly within the nervous system ([@bib18]; [@bib13]). Using combinations of pro-neuronal and region-/subtype-specific transcription factors, a variety of neuronal subtypes has been produced via direct conversion ([@bib4]; [@bib40]; [@bib47]; [@bib46]; [@bib45]).

Because iN conversion lacks a proliferating stem cell intermediate, the iN numbers obtained are largely dependent on conversion efficiency; therefore, great efforts have been undertaken to improve iN process yields. The identification and the combination of Ngn2 with Ascl1 as two pro-neuronal pioneer transcription factors that can induce neuronal identity in non-neuronal cells have been key features in the advancement of this technology ([@bib19]; [@bib21]; [@bib26]; [@bib50]; [@bib39]). The efficient delivery of Ngn2/Ascl1 into fibroblasts, and their robust, controllable transgene expression, left room for improvement and, because variations in the transduction and conversion efficiencies from different donors are common limitations, we have developed a new all-in-one lentiviral system for inducible Ngn2/Ascl1 expression called UNA.

Chemical modulation of several cellular signaling pathways has been shown to improve iN conversion and thus enable iN technology as a legitimate alternative to iPSC differentiation. Inhibition of TGF-b/SMAD signaling via blockade of AKT kinases, inhibition of GSK-3b signaling ([@bib19]), adenylyl cyclase activation ([@bib21]; [@bib19]; [@bib9]), inhibition of REST ([@bib25]; [@bib54]), induction of canonical Bcl-2 signaling, and inhibition of lipid oxidation pathways via ferroptosis inhibition ([@bib9]) have all been shown to greatly promote iN conversion. However, because these known signaling pathway modulators have either been adopted from iPSC differentiation ([@bib6]) or are the result of educated guessing or simply of trial-and-error experiments, no systematic efforts have been made to utilize broad and unbiased datasets to identify the pathways and corresponding modulators that orchestrate iN conversion. We sought to optimize the iN conversion media composition with small molecular pathway modulators to reach efficient iN conversion even in suboptimal human fibroblast lines. To that end, we have performed timeline RNAseq transcriptome analysis over the time course of direct iN conversion and have discovered four pathways that are instrumental in iN conversion. Based on these pathways, we identified four small molecules that could be combined into an improved iN conversion medium, ZPAK, which reliably boosted iN conversion of young and old fibroblasts into epigenetically age-equivalent iNs.

Results {#s2}
=======

An optimized all-in-one viral system simplifies fibroblast transduction and increases conversion efficiency {#s2-1}
-----------------------------------------------------------------------------------------------------------

Lentiviral delivery of pro-neuronal transcription factors is the most widely used technique for direct iN conversion due to its outstanding efficiency and relative ease to use ([@bib32]). Successful strategies involve the use of constitutive or inducible expression of either only a single pioneer factor, such as Ngn2 or Ascl1 ([@bib21]; [@bib39]), a combination of a pioneer factor with secondary factors ([@bib31]; [@bib49]), a combination of a pioneer factor with subtype-specifying transcription factors ([@bib4]; [@bib22]; [@bib46]); ([@bib45]), or the use of two coupled pioneer factors ([@bib19]; [@bib26]). Typically, these factors are distributed across several lentiviral vectors; however, given that lentiviral transduction is not 100% efficient and because an individual fibroblast must be transduced with two or more viruses to survive chemical selection and successfully reprogram, this strategy left room for improvement. To eliminate the need for co-infection, we combined the tetOn system cassette consisting of the rtTA~Adv~. \[Clonech\] driven by the UbC promoter, the iN cassette consisting of Ngn2:2A:Ascl1 under control of the TRE~tight~ promoter \[Clontech\], and a puromycin-resistance gene driven by the PGK promoter to yield the UNA construct ([Figure 1A](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). To test the efficiency of UNA compared to our conventional two-vector system (EtO +N2A), we selected fibroblasts from three individual donors that had not yielded optimal iN conversion efficiencies in the past ([Figure 1B](#fig1){ref-type="fig"} and [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}). Dermal fibroblasts were transduced with similar titers of either EtO +N2A or UNA, selected by puromycin or puromycin/G418, respectively, and converted to iNs using our previously described conversion medium (NC) containing noggin as well as the small molecules CHIR-99021 (GSK3ß inhibitor), SB-431542, LDN-193189, A-83--01 (ALK inhibitors), forskolin, and db-cAMP (cAMP increase) ([@bib26]; [@bib19]). Following three weeks of conversion, cells were live-stained for the neural surface marker PSA-NCAM, which stains reprogrammed iNs but not fibroblasts ([Figure 1C](#fig1){ref-type="fig"}). Flow cytometry revealed that UNA-derived iNs exhibited significantly more PSA-NCAM-positive cells than E + N2A, boosting efficiencies by up to 90--100% for the two suboptimal fibroblast lines, but also increasing efficiencies of the lines that already converted well by 30 ± 8% ([Figure 1D--E](#fig1){ref-type="fig"}). In addition, immunocytochemical co-staining for the neuronal markers ßIII-tubulin and NeuN revealed that UNA iNs were on average twice as likely to be positive for NeuN or ßIII-tubulin ([Figure 1F--H](#fig1){ref-type="fig"}). Based on these experiments, we reasoned that the use of the single all-in-one lentiviral vector UNA was notably easier and less prone to experimental error, as well as significantly more efficient in generating larger numbers of mature iNs compared to a multiple vector strategy.

![An optimized all-in-one viral system simplifies fibroblast transduction and increases conversion efficiency.\
(**A**) Schematic of all-in-one lentiviral system for inducible overexpression of N2A for iN conversion. (**B**) Cell lines of varying conversion efficiencies used for comparison (**C**) Immunocytochemical analysis of iNs following three weeks of conversion, stained with βIII-tubulin, PSA-NCAM, and DAPI. The scale bar represents 20 μm. (**D**) Flow cytometry histogram plots of PSA-NCAM:PE-stained iNs following 3 weeks of conversion with UNA (blue) or E:N2A (Orange) lentiviral systems. (**E**) Comparison of % PSA-NCAM:PE + cells from three three lines (L2,L5,L7) reprogrammed with E + N2A or UNA (3 biological and two technical replicates). (**F**) Immunocytochemical analysis of E:N2A or UNA iNs following three 3 weeks of conversion, stained with βIII-tubulin, NeuN, and DAPI. Scale bar represents 100 μm. (**G-H**) Quantification of immunocytochemical staining in **F**. (3 biological and two technical replicates).\
10.7554/eLife.41356.004Figure 1---source data 1.Human fibroblasts used in this study.](elife-41356-fig1){#fig1}

Time based RNAseq identifies signaling pathways directing iN conversion {#s2-2}
-----------------------------------------------------------------------

As pathways influential in controlling the direct conversion process continue to be found ([@bib25]; [@bib39]; [@bib44]; [@bib54]; [@bib21]; [@bib19]; [@bib9]), we decided to investigate the transcriptional dynamics during reprogramming to identify the pathways that orchestrate iN conversion. We gathered RNAseq data from bulk fibroblasts as well as cells undergoing conversion for 1, 2, 3, 6, 18, and 24 days (Line 10, [Figure 2A](#fig2){ref-type="fig"}). Using the Ingenuity Pathway Analysis software tool (IPA; Qiagen Inc), we identified more than 500 pathways called to be significantly transcriptionally enriched or depleted (−2 \> Z Score\>2) as conversion proceeded ([Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}); of these, we selected 10 of the most enriched pathways for further experimental testing ([Figure 2---source data 2](#fig2sdata2){ref-type="supplementary-material"}). Based on the regulated genes and overlap of the called pathways, we selected one small molecule activator and one inhibitor for each of the 10 pathways, with the strategy of initiating diametrically opposing regulation of a given pathway. Each of the 20 compounds had been previously been reported to be effective in tissue culture ([Figure 2---source data 2](#fig2sdata2){ref-type="supplementary-material"}). Preference was given to molecules that targeted an intersection of two or more called pathways rather than specifically targeting the canonical signaling cascade of one pathway. When screening for PSA-NCAM-positive cells by flow cytometry following 21 days in NC plus the respective compound, four compounds were found to significantly (p\<0.05) increase the frequency of PSA-NCAM-positive iNs ([Figure 2C--E](#fig2){ref-type="fig"}, [Figure 2---source data 2](#fig2sdata2){ref-type="supplementary-material"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}) Interestingly, the compound that acted in the opposite direction decreased iN conversion efficiency ([Figure 2C--D](#fig2){ref-type="fig"}, [Figure 2---source data 2](#fig2sdata2){ref-type="supplementary-material"}, and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). These four conversion booster compounds were Pyrintegrin (PY; Integrin activator), AZ960 (AZ; Jak2 inhibitor), ZM336372, (ZM; Raf-1 activator), and KC7F2 (KC; HIF1α inhibitor) ([Figure 2C](#fig2){ref-type="fig"}). The iNs derived in NC plus any of these four compounds resulted in a significant (p\<0.01) increase in the number of NeuN- and ßIII-tubulin-positive cells compared to those derived in NC medium alone ([Figure 2F--H](#fig2){ref-type="fig"}, [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). Importantly, the combination of all four compounds (ZPAK) resulted in an even higher iN yield than any of the compounds individually ([Figure 2F--H](#fig2){ref-type="fig"}, [Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}). This combination of all four molecules with the NC medium will henceforth be referred to as ZPAK.

![Time-based RNAseq identifies signaling pathways influential during iN conversion.\
(**A**) Schematic for timeline of RNA isolation during neuronal reprogramming of L10 (**B**) Activation Z-Score of the indicated signaling pathway as called by IPA Comparison Analysis during neuronal reprogramming. Z-Scores represent a statistical measure of the match between the expected relationship direction and observed gene expression of a given pathway, with z-scores \> 2 considered significant. (**C**) Description of small molecules selected to inhibit or activate branches of pathways identified in (**B**) Effect on iN conversion is based on increased % PSA-NCAM + cells by flow cytometry, with + indicating increased PSA-NCAM %, - reduced PSA-NCAM %, and = no effect on PSA-NCAM %. (**D**) Immunocytochemical analysis of neural markers in NC or NC+ZPAK iNs (L1, L5, L9) following three weeks of conversion, stained with βIII-tubulin, NeuN, and DAPI. Scale bar represents 100 μm. Representative image from L1. (**E**) flow cytometry quantification of %PSA-NCAM + cells in iNs (L1, L5, L9) converted in NC and NC+ZPAK supplements. (**F-H**) Quantification of immunocytochemical staining in (**D**). Results are shown as mean ± SEM. \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001; \*\*\*\*p\<0.0001, *n* = 3 biological replicates. Significance values were calculated by t test.\
10.7554/eLife.41356.010Figure 2---source data 1.Ingenuity pathway analysis of direct fibroblast to neuron conversion.\
10.7554/eLife.41356.007Figure 2---source data 2.Expanded small molecule information.](elife-41356-fig2){#fig2}

ZPAK induces a defined neuronal transcription that more closely relates to the adult brain transcriptome than NC alone {#s2-3}
----------------------------------------------------------------------------------------------------------------------

To investigate the changes induced on the transcriptional level by the ZPAK cocktail, we again performed time series RNAseq from fibroblasts from three donors that were converted to iNs in NC or NC+ZPAK for 5, 10, 15, and 20 days ([Figure 3A](#fig3){ref-type="fig"}; three biological replicates from four time points, 24 samples total). Comparing FPKM normalized gene counts for the conversion process for both conditions, we detected that the transcriptomes induced by NC or NC+ZPAK were highly correlated, with a Pearson correlation coefficient of ≥0.85 for all sampled time points ([Figure 3C](#fig3){ref-type="fig"}), indicating broad transcriptional similarities between the iN process in NC and NC+ZPAK. Comparing the top 100 upregulated and top 100 downregulated genes for the conversion process for both conditions, we detected an 80% and 93% overlap, respectively ([Figure 3B](#fig3){ref-type="fig"}). Consistently, glutamatergic neuron-specific genes Unc-13 homolog A (*UNC13A*), AMPA receptor auxiliary protein 2 (*CNIH2*), NMDA1 (*GRIN1*), GluK5 (*GRIK5*), GluK2 (*GRIK2*) and vGLUT1 (*SLC17A7*), and the GABAergic neuron-specific genes phospholipase C like 2 (*PLCL2*), dopamine receptor D2 (*DRD2*), cannabinoid receptor 1 (*CNR1*) and glutamate decarboxylase 1 (*GAD1*) were found to be generally expressed at similar levels in NC and NC+ZPAK at 20 days of conversion ([Figure 3D](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Markers of dopaminergic, serotonergic, and cholinergic lineages were not consistent in expression and were not commonly observed in D20 iNs ([Figure 3D](#fig3){ref-type="fig"}, [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). We next performed differential expression analysis between all NC and NC+ZPAK time points, revealing 143 genes that were significantly differentially expressed ([Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}, padj \< 0.05). Hierarchical clustering demonstrated a clear separation of NC and NC+ZPAK groups except for two NK samples at the earliest point of conversion ([Figure 3E](#fig3){ref-type="fig"}). These significant transcriptional differences point to a more defined neuronal transcriptome initiated in NC+ZPAK compared to NC. Interestingly, we observed consistently increased expression of neuron-specific genes *NCAM1/2* (Neural Cell Adhesion), *MNX1* (Neural Homeobox), *MAP2* (Neural Microtubule Protein), and *CAMK2* (Central Nervous System Kinase) in NC+ZPAK but lower expression levels of cyclins such as *CCND2* (Cyclin D2) as well as the myogenic factors *MEF2* (Myocyte Enhancer Factor) and *MYOG* (Myogenin), which are known to limit fibroblast to neuronal reprogramming, in NC+ZPAK ([Figure 3F](#fig3){ref-type="fig"}, [Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}, [Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}).

![ZPAK induces a more defined neuronal transcription that more closely relates to the adult brain transcriptome.\
(**A**) Schematic for timeline RNA isolation during neuronal reprogramming of L2, L5, and L7 at fibroblast and 5, 10, 15, and 20 days of conversion (**B**) Heatmap of FPKM normalized counts of the top 100 correlating (+) and top 100 inverse correlating (-) genes (FPKM ≥ 1) for day 5, 10, 15 and 20 of neuronal reprogramming with NC or NC+ZPAK. Orange = low expression, blue = high expression (**C**) Correlate R values of FPKM normalized counts from 25,610 genes during neuronal reprogramming with NC or NC+ZPAK cocktail. (**D**) Heatmap showing relative expression of the glutamatergic neuron-specific genes Unc-13 homolog A (UNC13A), AMPA receptor auxiliary protein 2 (CNIH2),NMDA1 (GRIN1), GluK5 (GRIK5), GluK2 (GRIK2) and vGLUT1 (SLC17A7), GABAergic neuron-specific genes phospholipase C like 2 (PLCL2), dopamine receptor D2 (DRD2), cannabinoid receptor 1 (CNR1) and glutamate decarboxylase 1 (GAD1), Serotonergic neuron-specific genes ETS transcription factor (FEV), serotonin transporter 1 (SLC6A4), and tryptophan hydroxylase (TPH1), Dopaminergic neuron-specific genes tyrosine hydroxylase (TH), dopamine transporter 1 (SLC6A3), forkhead box A2 (FOXA2), potassium voltage-gated channel subfamily J member 6 (KCNJ6), nuclear receptor subfamily four group A member 2(NR4A2), and LIM homeobox transcription factor one beta (LMX1B), and cholinergic neuron-specific genes vesicular acetylcholine transporter (SLC18A3), and choline O-acetyltransferase (ChAT); normalized by row. (**E**) Heatmap of 143 significantly (*p-adj* \< 0.05) differentially expressed genes between NC and NC+ZPAK at 5, 10, 15 and 20 days of reprogramming (*n* = 3). (**F**) FPKM normalized counts of five representative neuron specification genes - Neural Cell Adhesion Molecule 2 (NCAM2), Neural Cell Adhesion Molecule 1 (NCAM1), Motor Neuron and Pancreas Homeobox 1 (MNX1), Microtubule-associated Protein 2 (MAP2), Calcium/Calmodulin Dependent Protein Kinase II (CAMK2) - and three representative fibroblast-to-iN limiting genes - Cyclin D2 (CCND2), Myogenin (MYOG), and Myocyte enhancer factor-2 (MEF2) - over time during fibroblast-to-iN conversion with NC (orange) or NC+ZPAK (blue). (**G**) Gene ontology (GO) enrichment analysis of genes upregulated in NC or NC+ZPAK (log~2~FC \> 1). Results are shown as REVIGO ([@bib41]) scatterplots in which similar GO terms are grouped in arbitrary two-dimensional space based on semantic similarity. Each circle indicates a specific GO term and circle sizes are indicative of how many genes are included in each term, where larger circles indicate greater numbers of genes that are included in that GO term. Colors indicate the level of significance of enrichment of the GO term by log~10~ p-value. (**H**) Rank-rank hypergeometric overlap (RRHO) map ([@bib33]) comparing the gene expression differences between NC and NC+ZPAK to expression differences between matched fibroblasts and adult human brain (Allen Brainspan). Each pixel represents overlap between NC or NC+ZPAK to fibroblast or adult brain transcriptome, color-coded according to the --log~10~p value of a hypergeometric test (step size = 100). On the map, the extent of shared genes upregulated in NC+ZPAK and adult brain is displayed in the top right corner, whereas the shared genes upregulated in NC and fibroblasts are displayed in the bottom left corner (see schematic in [Figure 3---figure supplement 6](#fig3s6){ref-type="fig"}).\
10.7554/eLife.41356.018Figure 3---source data 1.Significantly differentially expressed genes between NC and NC+ZPAK.](elife-41356-fig3){#fig3}

Next, gene ontology (GO) enrichment analysis revealed that genes upregulated in NC (log2FC \> 1) were only enriched for three neuronal GO terms - GO:0034220 Ion transmembrane transport, GO:0006811 ion transport, and GO:0099537 Trans-synaptic signaling - whereas GO terms enriched in genes upregulated in NC+ZPAK included many GO terms categorized for neural development (GO:0021953 Central Nervous System Neuron Differentiation, GO:0007272/0008366 Ensheathement of Neurons/Axons, GO:0021700 Developmental Maturation), synapse development (GO:0007416 Synapse Assembly, GO:0050808 Synapse Organization, GO:0007268 Chemical Synaptic Transmission), neural activity (GO:0001964 Startle Response), and membrane potential maintenance (GO:0006811,0098660,0006811 Regulation of Ion Transport, Inorganic Ion Transport, Ion Transport) ([Figure 3G](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}; [@bib41]). When comparing the average and median expression of the genes in these GO terms, we observed consistent upregulation in NC+ZPAK ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). These data indicate that NC+ZPAK yields iNs with a more defined and probably more human brain-like transcriptional profile. To assess neuronal enrichment in a threshold-free manner, and to quantify overlap of expression with adult brain, we employed the rank-rank hypergeometric overlap (RRHO) test ([@bib33]). Briefly, this method generates a map of the transcriptional overlap between any two systems by comparing two ranked lists of differentially expressed genes. We applied this method to compare the overlap of NC versus NC-ZPAK to fibroblast versus adult brain (Allen Institute) to evaluate the extent to which either condition more closely resembled adult brain gene expression. Using RRHO, we observed a pronounced bias in the overlap of NC-ZPAK with adult brain, indicating that, relative to NC, NC-ZPAK iNs were indeed more similar to brain expression patterns ([Figure 3H](#fig3){ref-type="fig"}). To make a direct comparison of the functional maturity of NC to NC+ZPAK iNs, we performed calcium imaging of NC and NC+ZPAK iNs, revealing that NC+ZPAK iNs have more spontaneous calcium transients than iNs cultured in NC alone ([Figure 3---figure supplement 5](#fig3s5){ref-type="fig"}). As calcium transients have been established as a reliable readout of neural activity in vitro, this direct comparison between NC and NC+ZPAK iNs provides further evidence that ZPAK is producing a more mature and defined neuronal state ([@bib35]). Taken together, these data indicate that NC-ZPAK iNs possess a transcriptional profile more closely resembling that of mature neurons and that the original fibroblast transcriptional program, as well as other non-neuronal directions, were substantially reduced or absent.

To gain a better understanding of how each of the four pathway modulators improves iN conversion, we sought to obtain a more detailed understanding of the individual processes influenced by ZM, PY, AZ, and KC.

Inhibition of JAK2 removes fibroblasts from the cell cycle and promotes mesenchymal-to-epithelial transition (MET) {#s2-4}
------------------------------------------------------------------------------------------------------------------

Removal of fibroblasts from the cell cycle has been reported to improve neuronal reprogramming ([@bib16]; [@bib21]). Based on the enrichment of the IGF-1 signaling and the specific transcriptional footprint called by the IPA software, we selected the JAK2 inhibitor AZ as a promising and well-characterized inhibitor, because IGF1/IGF1R is known to enhance cell cycle entry of fibroblasts ([@bib24]; [@bib10]) and signals through the JAK2 substrate STAT3 ([@bib52]; [@bib29]; [@bib57]) ([Figure 4A](#fig4){ref-type="fig"}). We therefore asked whether AZ removed fibroblasts from the cell cycle to enable direct conversion. As expected, Western blot analysis for STAT3 revealed that converting fibroblasts cultured in NC showed a decrease in STAT3 within the first six days of conversion, and the addition of AZ strongly promoted this decrease ([Figure 4B](#fig4){ref-type="fig"}). Using carboxyfluorescein succinimidyl ester (CFSE) to examine cell divisions by flow cytometry, we consistently detected that fibroblasts cultured with 0.1 μM AZ or ZPAK went through significantly fewer divisions than fibroblasts cultured in control medium ([Figure 4C,D](#fig4){ref-type="fig"}). Importantly, flow cytometry for DAPI staining did not detect elevated toxicity in AZ-treated cells. Change in the cell phenotype from multipolar mesenchymal cells to polarized epithelial cells is an important developmental process known as the mesenchymal-epithelial transition (MET) ([@bib5]). MET machinery plays an important role during direct conversion of fibroblasts to neurons ([@bib12]), and p-STAT3 dimers directly promote epithelial-to-mesenchymal transition (EMT)-related gene expression ([@bib51]). Perturbations in STAT3 signaling have been linked to MET ([@bib56]; [@bib34]). Therefore, we monitored the E-Cadherin to N-Cadherin switch during iN conversion in NC and in NC + AZ ([@bib28]; [@bib20]) and found that AZ induced a more rapid switch towards E-Cadherin ([Figure 4D](#fig4){ref-type="fig"}), a switch that is a classic hallmark of MET ([@bib37]; [@bib55]).

![Cellular mechanisms influenced by ZPAK-mediated reprogramming.\
(**A**) Schematic diagram of AZ targeting confluence of IGF1R and JAK2 signaling pathways. (**B**) Western blot analysis of protein levels of STAT3 assessed at one, three, and six days in L6 fibroblast media containing PY, ZM, AZ or control media. (**C**) CFSE stained L1, L5, and L8 fibroblasts cultured with control, AZ-containing medium, or ZPAK-containing medium for 48 hours after plating at 50% confluency. Boxes indicate percentages of cells that have undergone at least one cellular division. (**D**) Quantification of % dividing cell reduction in ZPAK from C. Results are shown as mean ± SD. n = 3, \*\* P \< 0.01. Significance values were calculated by t-test. (E) Two color flow cytometry analysis of E- cadherin (E-Cad) and N-cadherin (N-Cad) expression in L10 and L6 fibroblast-to-iN conversion in NC or NC+AZ. Increasing ratios of E-Cad/N-Cad are indicative of the mesenchymal-to-epithelial switch. (**F**) Representative Neurolucida reconstruction of L1 reprogrammed for 21 days in NC or NC+ZPAK medium. Scale bar 100 μm (**G**) Neurolucida complexity scores of iNs derived from NC or NC+ZPAK components. Complexity scores were normalized to cell number by counterstaining with DAPI to count cell bodies. Results are shown as mean ± SD. n = 3, \* P \< 0.05. (**H**) Schematic diagram of PY and ZM interaction with cytoskeletal dynamics. (**I**) L1 fibroblasts cultured for 48h with ZM, PY, or CTL medium labeled for F-Actin with FITC Phallodidin and nuclei with DAPI. Scale bar 20 μm. (**J**) Integrated signal density of FITC phalloidin stain from H. Signal density was normalized to cell numbers by DAPI. Results are shown as mean ± SEM. n = 3, \*\*\* P \< 0.001. (**K**) Schematic diagram of KC targeting HIF1α to inhibit glycolysis and promote oxidative phosphorylation (OXPHOS). (**L**) Mitochondria in L10, L4, & L2 iNs cultured for 21 days in NC or NC+KC stained with JC-1 and measured for membrane depolarization by flow cytometry. Increased ratios of aggregate (PE) to diffuse (FITC) JC-1 are indicative of increased mitochondrial membrane potential. Results are shown as mean ± SD. n = 3. Significance values were calculated by t-test.](elife-41356-fig4){#fig4}

Activation of integrin and rho signaling promotes neuronal complexity {#s2-5}
---------------------------------------------------------------------

The morphological changes a fibroblast has to undergo to transform into a neuron are substantial, and we have observed a pronounced increase in neuronal complexity in ZPAK compared to NC ([Figure 2B](#fig2){ref-type="fig"}). To determine which ZPAK molecules primarily facilitate these structural modifications, we used ßIII-tubulin-based tracing and scoring to assess the neuronal complexities of iN cultures derived in NC containing either PY, ZM, AZ, or KC; we found that both PY and ZM produced significantly increased complexity scores ([Figure 4E--F](#fig4){ref-type="fig"}). Interestingly, PY was shown previously to promote integrin β1 stability and signaling of human pluripotent stem cells ([@bib53]), and we reasoned that PY also enhanced integrin-dependent attachment to extracellular matrices of iNs, thereby promoting neurite outgrowth and interactions ([Figure 4G](#fig4){ref-type="fig"}). Based on the fact that ZM is a Raf-1 activator, we reasoned that the structural complexity increase in NC + ZM was associated with increased F-actin activity ([Figure 4G](#fig4){ref-type="fig"}). Thus, we stained fibroblasts cultured with ZM or PY for 48 hr with fluorescent phalloidin, which revealed a marked increase in phalloidin signal by ZM and also a significant increase by PY ([Figure 4H--I](#fig4){ref-type="fig"}). These results are consistent with the reported roles of Raf-1 activation and actin polymerizations in organizing cytoskeletal shape and neuronal morphology ([@bib8]; [@bib14]; [@bib3]), and they suggest that ZM and PY promote morphological rearrangements that occur during direct neuronal reprogramming by different but overlapping means.

Inhibition of HIF1α signaling promotes oxidative phosphorylation in iNs {#s2-6}
-----------------------------------------------------------------------

Consistent with our timeline transcriptome data, the transcription factor HIF1α has been reported to be one of the top downregulated factors during direct neuronal conversion from a variety of originating cell types ([@bib30]). Increased oxidative phosphorylation is a hallmark of neuronal identity, and glycolysis has been reported to limit neural reprogramming in many protocols ([@bib58]; [@bib9]; [@bib1]). As HIF1α is a major inhibitor of oxidative phosphorylation (OXPHOS) and a mediator of glycolysis, we hypothesized that KC, a HIF1α inhibitor, improved iN conversion by facilitating OXPHOS ([Figure 4J](#fig4){ref-type="fig"}). Using the JC1 dye, a cationic dye that accumulates in energized mitochondria with high membrane potentials ([@bib38]), we found that cultures at one, two and three weeks of conversion had higher mitochondrial membrane potentials in the presence of KC at all time points and significantly higher mitochondrial membrane potentials by week three ([Figure 4K](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). These data are consistent with a HIF1α blockade initiated by KC promoting the metabolic switch towards OXPHOS that is necessary for iN conversion.

Epigenetic signatures of donor age are preserved in ZPAK-derived iNs {#s2-7}
--------------------------------------------------------------------

One unique characteristic of direct iN conversion compared to iPSC reprogramming and subsequent neuronal differentiation is the retention of the cellular marks of aging ([@bib26]; [@bib42]; [@bib48]; [@bib22]). As our additional ZPAK pathway modulators might impact the cellular age of the derived iNs, we sought to verify that ZPAK did not affect the epigenetic age of derived iNs based on age-dependent DNA methylation ([@bib17]). Similar to other global aging features, age-dependent DNA methylation of CpGs has been shown to be preserved in iNs ([@bib15]) and reverts to a predicted prenatal age even in iPSCs from donors older then 90 years of age ([@bib23]). We quantified CpG methylation for 850,000 sites for two young (0 and 1 years), two middle age (both 29 years), and two old (71 and 87 years) purified iN cultures in NC+ZPAK, as well as one young (1 year) and one old (87 years) unconverted fibroblast culture. Based on the top 5000 differentially methylated regions identified using ChAMP ([@bib27]), we observed a clear difference between young and old donors, with middle-age donors showing an intermediate age-dependent CpG methylation pattern ([Figure 5A](#fig5){ref-type="fig"}). Most importantly, the methylation patterns of the young and old NC+ZPAK iNs were largely unchanged compared to their parental fibroblasts ([Figure 5A](#fig5){ref-type="fig"}). To apportion the majority of the variation, principal component analysis (PCA) based on all 850,000 CpGs consistently clearly separated the samples with respect to their age as the strongest component ([Figure 5B](#fig5){ref-type="fig"}). Taken together, these results indicate that age-dependent DNA methylation patterns are maintained during ZPAK-assisted iN conversion and that NC + PAKZ is suitable to efficiently generate human neuronal models that recapitulate age-associated epigenetic changes.

![Epigenetic signatures of donor age are preserved in ZPAK-derived iNs.\
(**A**) Heat map showing the top 5000 significantly (padj \< 0.05) differentially methylated CpGs between iNs generated by NC+ZPAK from two young (0, 1 years), two middle age (29 years), and two old (71, 87 years) donors, and one young and one old untreated fibroblast (0, 87 years, respectively). Each line represents a single probe. High methylation levels are shown in yellow, low methylation is shown in blue. Methylation of one young and one old paired, unconverted fibroblast is shown next to its iN counterpart. (**B**) Principal Component Analysis (PCA) of the methylation profiles of two young iNs, one young fibroblast, two middle age iNs, two old iNs, and one old fibroblast cell line. All iNs were reprogrammed with NC+ZPAK medium. Plot shows principal component one and principal component two for each sample. Samples closer to each other in principal component space are similar in their methylation profiles.](elife-41356-fig5){#fig5}

Discussion {#s3}
==========

Significant gaps remain in our understanding of the mechanisms influencing neuronal specification during direct reprogramming. Consequently, iN yields from current protocols are often paltry, necessitating large numbers of converting cells to get sufficient successfully reprogrammed iNs for experimental analysis. Further, improvements to these protocols are largely based on trial and error, with few predictive tools available. In this study, we leveraged RNAseq data to uncover several key molecular events that can be targeted with small molecules to improve iN yield. These modifications, combined with our streamlined lentiviral system, provide a state-of-the-art improvement in current iN direct reprogramming protocols and shed insight into mechanisms driving neuronal specification during reprogramming.

Efficiently overcoming competing cellular programs has long been a challenge in the somatic reprogramming field. Here, we report that ZPAK causes a more thorough elimination of competing fibroblast programs on the transcriptional level than classic medium, as represented by both upregulation of neuron-specific genes and, importantly, downregulation of myogenic and fibroblast-specific genes known to limit neuronal specification during late reprogramming. These transcriptional changes are accompanied by other important phenotypes associated with neuronal fate, including removal of cells from the cell cycle, increased mitochondrial membrane potential, increased GCAMP activity, and enhanced mesenchymal to epithelial plasticity. There has also been an increased recognition of the important role of cytoskeleton remodeling during somatic cell reprogramming ([@bib36]; [@bib11]). Neurons have elaborate cytoskeleton structures that are highly specialized and critical for proper function. As the morphological changes from a fibroblast to a neuron are substantial, we were interested to discover that two of our compound modifications, ZM and PY, were associated with increased neuronal morphological complexity in addition to increasing iN yield. This phenotype was accompanied by an increase in F-Actin activity, a potent component of cellular plasticity. Cytoskeleton remodeling is associated with sheer stress, and the actin cytoskeleton can sense and respond to these stresses with apoptotic signals. Therefore, we propose that the inclusion of ZM and PY in direct neuronal reprogramming could promote cytoskeleton reorganization and spare converting fibroblasts from mechanical stress-induced apoptosis. Our findings illustrate the important contribution actin structure makes during reprogramming and suggests that increased cellular structural plasticity could be a fruitful strategy for improving neuronal lineage commitment during reprogramming.

Classic direct conversion protocols, which we and others have used to differentiate fibroblasts to mature human neurons, are highly inefficient and fail to successfully reprogram the majority of input cells. Additionally, a significant heterogeneity exists in the reprogrammed pool, with many cells existing in a state that is not quite fibroblast, not quite neuron. Although many relevant phenotypes have been found between patient and control neuronal cultures reprogrammed in currently used media, we predict that new phenotypes might be revealed from studying neurons in conditions that more thoroughly commit fibroblasts to neuronal fate specification and, in turn, might lead to the discovery of more effective treatments for neurological disorders. Further, as iNs have shown promise in cell replacement therapies, we propose that using culture conditions that completely commit fibroblasts to the neuronal lineage will result in an increased therapeutic potential of iNs for possible neuronal replacement. Importantly, ZPAK improves iN yields even at very late fibroblast passages that could be required to produce therapeutic numbers of cells ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Although 100% efficiency in establishing neuronal specification remains elusive, the development of new neuronal reprogramming techniques, such as UNA and ZPAK media, takes us one step closer to this goal.

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\           Designation               Source or reference   Identifiers                                                      Additional\
  (species) or resource                                                                                                                    information
  ----------------------- ------------------------- --------------------- ---------------------------------------------------------------- -------------
  Chemical\               AZ960                     Cayman                RRID:[SCR_008945](https://scicrunch.org/resolver/SCR_008945)     
  compound, drug                                                                                                                           

  Chemical\               Pyrintegrin               Tocris                RRID:[SCR_003689](https://scicrunch.org/resolver/SCR_003689)     
  compound, drug                                                                                                                           

  Chemical\               ZM336372                  Cayman                RRID:[SCR_008945](https://scicrunch.org/resolver/SCR_008945)     
  compound, drug                                                                                                                           

  Chemical\               KC7F2                     Fischer Scientific    RRID:[SCR_008452](https://scicrunch.org/resolver/SCR_008452)     
  compound, drug                                                                                                                           

  Chemical\               Phalloidin\               SCBT                  RRID:[AB_2631056](https://scicrunch.org/resolver/AB_2631056)     '1:1000'
  compound, drug          CruzFluor 488\                                                                                                   
                          Conjugate                                                                                                        

  Antibody                N-Cadherin\               Miltenyi Biotec       RRID:[AB_2727381](https://scicrunch.org/resolver/AB_2727381)     '1:50'
                          (Mouse monoclonal)                                                                                               

  Antibody                E-Cadherin\               Miltenyi Biotec       RRID:[AB_10827695](https://scicrunch.org/resolver/AB_10827695)   '1:11'
                          (Mouse monoclonal)                                                                                               

  Antibody                STAT3\                    Cell Signaling        RRID:[AB_2716836](https://scicrunch.org/resolver/AB_2716836)     '1:1000'
                          (Rabbit monoclonal)                                                                                              

  Antibody                Anti-NeuN\                EMD Millipore         RRID:[AB_2298772](https://scicrunch.org/resolver/AB_2298772)     '1:200'
                          (Mouse monoclonal)                                                                                               

  Antibody                Anti-Tubulin\             Covance               RRID:[AB_2313773](https://scicrunch.org/resolver/AB_2313773)     '1:3000'
                          β−3 (Rabbit polyclonal)                                                                                          

  Antibody                Anti-GABA\                Sigma                 RRID:[AB_477652](https://scicrunch.org/resolver/AB_477652)       '1:500'
                          (Rabbit polyclonal)                                                                                              

  Antibody                Anti-vGlut1\              Synaptic Systems      RRID:[AB_887875](https://scicrunch.org/resolver/AB_887875)       '1:100'
                          (Rabbit polyclonal)                                                                                              

  Antibody                Anti-TH\                  Pel-Freez             RRID:[AB_2313713](https://scicrunch.org/resolver/AB_2313713)     '1:250'
                          (Rabbit polyclonal)                                                                                              

  Antibody                Anti-ChAT\                EMD Millipore         RRID:[AB_10615776](https://scicrunch.org/resolver/AB_10615776)   '1:100'
                          (Goat polyclonal)                                                                                                

  Antibody                Anti-5-HT\                Protos Bio Tech       RRID:[AB_2313881](https://scicrunch.org/resolver/AB_2313881)     '1:1000'
                          (Rabbit polyclonal)                                                                                              

  Antibody                Anti-PSANCAM\             Miltenyi Biotec       RRID:[AB_1036069](https://scicrunch.org/resolver/AB_1036069)     '1:50'
                          (Mouse monoclonal)                                                                                               

  Antibody                anti-MYH\                 Santa Cruz\           RRID:[AB_10989398](https://scicrunch.org/resolver/AB_10989398)   '1:100'
                          (Mouse monoclonal)        Biotechnology                                                                          

  Chemical\               Cell Trace CFSE           ThermoFisher\         C34554                                                           
  compound, drug                                    Scientific                                                                             

  Commercial\             Mito Probe JC-1           ThermoFisher\         M34152                                                           '1:1000'
  assay or kit                                      Scientific                                                                             

  Software,\              Ingenuity\                QIAGEN\               RRID:[SCR_008653](https://scicrunch.org/resolver/SCR_008653)     
  algorithm               Pathway Analysis          Bioinformatics                                                                         
  ------------------------------------------------------------------------------------------------------------------------------------------------------

Direct conversion of human fibroblasts into iNs {#s4-1}
-----------------------------------------------

Primary human dermal fibroblasts from donors between 0 and 88 years of age were obtained from the Coriell Institute Cell Repository, the University Hospital in Erlangen and Shiley-Marcos Alzhiemer's Disease Research Center ([Figure 2---source data 2](#fig2sdata2){ref-type="supplementary-material"}). Protocols were previously approved by the Salk Institute Institutional Review Board and informed consent was obtained from all subjects. Fibroblasts were cultured in DMEM containing 15% tetracycline-free fetal bovine serum and 0.1% NEAA (Thermo Fisher Scientific), transduced with lentiviral particles for EtO and XTP-Ngn2:2A:Ascl1 (E + N2A), or the combined tetOn system cassette consisting of the rtTAAdv. \[Clonech\] driven by the UbC promoter, Ngn2:2A:Ascl1 under control of the TREtight promoter \[Clontech\], and a puromycin-resistance gene driven by the PGK promoter (UNA, [Figure 1A](#fig1){ref-type="fig"}) and expanded in the presence of G418 (200 µg/ml; Thermo Fisher Scientific) and puromycin (1 µg/ml; Sigma Aldrich), or puromycin only, respectively, as 'iN-ready' fibroblast cell lines. Following at least three passages after viral transduction, 'iN-ready' fibroblasts were trypsinized and pooled into high densities (30.000--50.000 cells per cm^2^; appx. a 2:1 -- 3:1 split from a confluent culture) and, after 24 hr, the medium was changed to neuron conversion (NC) or NC+ZPAK medium based on DMEM:F12/Neurobasal (1:1) for three weeks. NC contains the following supplements: N2 supplement, B27 supplement (both 1x; Thermo Fisher Scientific), doxycycline (2 µg/ml, Sigma Aldrich), Laminin (1 µg/ml, Thermo Fisher Scientific Scientific), dibutyryl cyclic-AMP (500 µg/ml, Sigma Aldrich), human recombinant Noggin (150 ng/ml; Preprotech), LDN-193189 (5 µM; Fisher Scientific Co) and A83-1 (5 µM; Santa Cruz Biotechnology Inc), CHIR99021 (3 µM, LC Laboratories), Forskolin (5 µM, LC Laboratories) and SB-431542 (10 µM; Cayman Chemicals). ZPAK contains the following supplements: Pyrintegrin (1 µM; Tocris), ZM336372 (0.175 µM; Cayman), AZ960 (0.1 µM; Cayman), and KC7F2 (7.5 µM; Fischer Scientific). Medium was changed every third day. For further maturation up to six weeks, iNs were switched to BrainPhys (STEMCELL Technologies)-based neural maturation media (NM) containing N2, B27, GDNF, BDNF (both 20 ng/ml, R and D), dibutyryl cyclicAMP (500 µg/ml, Sigma Aldrich), doxycycline (2 µg/ml, Sigma-Aldrich) and laminin (1 µg/ml, Thermo Fisher Scientific). For maturation on astrocytes for morphological analysis and calcium imaging, iNs were carefully trypsinized during week four and replated on a feeder layer of mouse astrocytes and cultured in NM media containing 1% KOSR (Thermo Fisher Scientific).

Whole transcriptome mRNA sequencing and methylation array {#s4-2}
---------------------------------------------------------

Total bulk RNA was extracted from fibroblasts and converting iNs at all collected time points using Trizol LS reagent (Thermo Fischer). RNA integrity (RIN) numbers were assessed using the Agilent TapeStation before library preparation. RNA-Seq libraries were prepared using the TruSeq Stranded mRNA Sample Prep Kit according to the manufacturer's instructions (Illumina). Libraries were sequenced single-end 50 bp using the Illumina HiSeq 2500 platform. Read trimming was performed using TrimGalore, read mapping was performed using STAR, raw counts were generated using HTseq variance stabilizing transformation normalization (vst) and differential expression analysis was performed in DEseq2. Pathway and network analysis was performed using Ingenuity Pathway Analysis (Qiagen) from FPKM normalized HTseq generated gene counts under the time course analysis module. Pathways with a Z-Score ≥ 3 (99% confidence interval) were considered for further study.

Total genomic DNA was extracted from bulk fibroblasts and flow cytometry sorted PSA-NCAM + 21 day iNs as described below with the DNeasy Blood and Tissue Kit (Qiagen). DNA methylation assays were performed on the MethylationEPIC BeadChip as per the standard manufacturer's protocol (Illumina). Raw intensity idat files were processed and analyzed using the R packages ChAMP ([@bib27]) or Rnbeads ([@bib2]); arrays were normalized using the BMIQ procedure ([@bib43]).

Flow cytometry assessment of PSA-NCAM, ECAD/NCAD, Cell Proliferation, and Mitochondrial Membrane Polarization {#s4-3}
-------------------------------------------------------------------------------------------------------------

For PSA-NCAM analysis, iNs were detached using TrypLE and stained for PSA-NCAM directly conjugated to PE (Miltenyi Biotec; 1:50) for 1 hr at 4°C in sorting buffer (250 mM myo-inositol and 5 mg/ml polyvinyl alcohol, PVA, in PBS) containing 1% KOSR. Cells were washed and resuspended in sorting buffer containing EDTA and DNAse and filtered using a 40 µm cell strainer. For co-staining with NCAD and ECAD, cells were detached and prepared as above and stained for N-CAD:APC (Miltenyl Biotec, CD325, 1:20) and E-CAD:PE (Miltenyl Biotec, CD324, 1:11). To determine the effect of AZ960 on proliferation of fibroblast cell lines, the cellular divisions were quantified with the CellTrace CFSE proliferation assay (Thermo Fisher). 1.2 × 10^6^ fibroblasts at full density on a single well of a six-well plate (9 cm^2^) were split into two 60 mm plates (21 cm^2^) and proliferated in DMEM containing 15% tetracycline-free fetal bovine serum and 0.1% NEAA (Life Technologies), 2.5 µM of CellTrace CFSE proliferation dye (Invitrogen), and 0.1 µM AZ960 for 48 hr. Mitochondrial membrane potential was analyzed using the MitoProbe JC-1 assay kit (Thermo Fisher, M34152). In all cases analysis was conducted on the FACS Canto II platform.

Image collection and analysis {#s4-4}
-----------------------------

Cells were transferred to tissue culture-treated ibidi µ-slides for imaging. Cells were fixed with 4% PFA for 20 min at room temperature and washed 3 × 15 min with TBS, followed by a 1 hr block with TBS + 4% bovine serum albumin and 0.1% Triton X-100 (TBS++). Primary antibodies (Anti-NeuN, 1:200, EMD Millipore; Anti-ßIII-tubulin, 1:3000, Covance; Phalloidin CruzFluor 488 Conjugate, 1:1000, SCBT) were applied overnight at 4°C. After washing as described above, samples were incubated in 1:250 donkey anti-mouse, chicken, or rabbit secondary antibody for 2 hr at room temperature. Nuclear staining was done with DAPI (1/10,000; Sigma-Aldrich). After washing, slides were mounted in PVA-DAPCO (Sigma Aldrich). Confocal images were taken on Zeiss LSM780 or Zeiss AiryScan series confocal microscope. All data for one experiment were acquired from cells cultured and processed in parallel on the same microscope with the exact same setting reused. For analysis, 2 µm confocal sections through the nuclear layer were acquired from three confocal z stacks. Neurolucida software was used for manual tracing of entire neuronal processes, and data were analyzed using NeuroExplorer (MicroBrightField Inc). All tracings were performed in a blinded manner. For phalloidin staining, automatic thresholding in ImageJ was used to binarize the images and green fluorescence intensity was calculated minus background intensity. At least 50 different cells were analyzed in each experiment, and the mean ± SEM optical density (OD) was then calculated.

Calcium Imaging {#s4-5}
---------------

iNs converted in NC or NC+ZPAK were transduced with lentiviral particles for CAG-GCAMP5G and LV-hSyn-dsRed at 21 days of conversion and replated on astrocytes for maturation as described above. Calcium imaging were performed four weeks after plating on astrocytes. Imaging was performed in BrainPhys media (Stemcell Technologies) on a Yokogawa Cell Voyager 1000 Spinning Disk Confocal Microscope. We only analyzed 10 cells per field that were hSyn-dsRed + and exhibited neuron identity. Calcium responses were calculated as the change in fluorescence intensity (Δ*F*) over the initial fluorescence intensity (F-F~0~)/F~0~,in which F is the fluorescence at a given time point and F~0~ was calculated as the average of the first five inactive fluorescence measurements at the start of imaging. A non-response area for each recording was measured for background subtraction, and imaging bleach was corrected for using the ImageJ plugin Fiji (NIH, Bethesda, MD). The threshold for a positive calcium event was defined as local maxima when fluorescence response within a soma exceeded a value greater than three standard deviations above the mean.

SYBR qPCR {#s4-6}
---------

Bulk mRNA was extracted as described above, and 1 μg of RNA was then reverse transcribed using the Superscript III Reverse Transcriptase kit (Thermo Fisher). Quantitative differences in gene expression were determined by real-time qPCR using SYBR Green Master Mix (Bio-Rad) and a spectrofluorometric thermal cycler (CFX384, Bio-Rad). Values are presented as the ratio of target mRNA to GAPDH expression obtained for each time point and treatment. Primer sequences used are the following:

1.  MNX1: GATGCCCGACTTCAACTCCC, GCCGCGACAGGTACTTGTT

2.  MAP2: CTCAGCACCGCTAACAGAGG, CATTGGCGCTTCGGACAAG

3.  CCND2:TTTGCCATGTACCCACCGTC, AGGGCATCACAAGTGAGCG

4.  MYOG: GGGGAAAACTACCTGCCTGTC, AGGCGCTCGATGTACTGGAT

5.  MEF2C: CTGGTGTAACACATCGACCTC, GATTGCCATACCCGTTCCCT

6.  NCAM1: GTCCTGCTCCTGGTGGTTGT, TGACCGCAATGCACATGAA

7.  NCAM2: GACGTGCCATCCAGTCCCTA, ATGGGAGTCCGGTTTGTTGA

8.  CAMK2A: AACCTTGGCTCCAGCATGAA, AAGGGAGACAGGAGGCCTTG

9.  GAPDH: TGCACCACCAACTGCTTAGC, GGCATGGACTGTGGTCATGAG

Western blot analysis {#s4-7}
---------------------

Cell lysates were prepared in Lysis buffer A (20 mM Tris pH 7.5, 100 mM NaCl, 1 mM EDTA, 2 mM EGTA, 50 mM β -glycerophosphate, 50 mM NaF, 1 mM sodium vanadate, 2 mM dithiothreitol, proteinase inhibitor cocktail (Roche) and 1% Triton X-100 and subjected to Western blot according to the standard procedures. The primary antibody used was rabbit mAb STAT3 (1:1000, Cell Signaling, 79D7, \#4904).

Statistical analysis {#s4-8}
--------------------

Statistical values for RNA-Seq and CpG methylation data were corrected for false discovery rates (FDR) using the Benjamini-Hochberg method implemented in R. Statistical tests of quantitative data were calculated using GraphPad Prism seven software, with the method indicated for each figure. Significance evaluation are marked as \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.005 and \*\*\*\*p\<0.001.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Chemical modulation of transcriptionally enriched signaling pathways to optimize conversion of fibroblasts into neurons\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Marianne Bronner as the Senior Editor. The following individual involved in review of your submission has agreed to reveal her identity: Marisa Karow (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The paper by Herdy et al. describes an interesting attempt to improve the process by which neurons are produced directly from patient fibroblasts. The theoretical advantage of such a method, should it be sufficiently efficient, is that it may be capable of preserving some of the epigenetic changes, occurring during aging or other conditions, in the neurons. The authors formulated a method that uses a revised lentiviral vector that drives the expression of two different neurogenic transcription factors along with a combination of small molecule signaling modulators. Overall, the new method appears to result in a substantial improvement in the production of induced neurons, including from a few patient lines that were \"low performers\" under the original induction conditions.

The three reviewers agree that this manuscript is worth publishing after a set of focused experiments are performed. Most of the comments are directed at achieving a greater understanding of the actions of the small molecules. Some additional information concerning the consistency of the effects of ZPAK on different sets of fibroblasts and on the total scalability of the new differentiation protocol are also requested. Since this is a Resource and Tools paper, we have tried to restrict the requests to ones that we agree will make the protocols more useful and comprehensive.

Essential revisions:

1\) Analyzing effects of treatment with single compounds and with ZPAK.

Can the authors clarify:

• Which fibroblast line(s) were used for the analyses in Figure 2 and subsequent figures?

• Whether they tested multiple inhibitors and activators of the same pathways to generate the data for Figure 1. If they tested multiple, did they all work to some degree or were the results more mixed?

• How well ZPAK works across the different patient lines?

• If they compared the effects of ZPAK to those of the individual compounds based on testing single compound concentrations? Were the concentrations chosen from prior literature or from dose-response experiments that they performed? In either case, additional data to ensure that even single compounds at more optimal concentrations wouldn\'t have comparable effects to those of ZPAK should be included.

2\) Understanding the effects of small molecule signaling modulators.

*Reviewer 2:*

Following NC+ZAPK treatment and Ngn2/Ascl1 expression, the fibroblasts adopt a mixed neuronal phenotype as assessed on a molecular level (Figure 3D). Are any of the neuronal branches adopted with higher frequency? Is there a change when switching from NC to NC+ZAPK? Did the authors check for this via immunofluorescence or electrophysiology?

The authors mention the alternative myogenic fate (as induced by Ascl1 alone in murine fibroblasts (Treutlein et al., 2016) being more highly expressed in the NC condition as compared to NC+ZPAK. Could they confirm this via staining?

In Figure 4C the authors show that AZ-treated cells went through significantly fewer divisions. Was cell division assessed in NC+ZAPK versus NC? In Figure 4E it looks like there are more cells in NC+ZAPK.

*Reviewer 3 (reviewer 1 had similar questions to those described clearly below):*

Comparing NC and NC+ZPAK in Figure 3, it appears the authors used bulk fibroblasts undergoing iN conversion at days 5, 10, 15 and 20. However, given the boost in conversion efficiency with ZPAK (Figures 2D-H), could the fact that there are more neurons and fewer fibroblasts in the NC+ZPAK conversion condition compared to the NC condition account for the increased \'adult / defined\' neuronal signature? Can the authors rule out a change in cell ratios and ability to detect small transcript changes in a sub-population rather than changes to the neuron population specifically? In order to conclude that NC+ZPAK not only improves efficiency of conversion but also generates neurons that are more \'human brain-like\' the authors need to compare NC neurons to NC+ZKAK neurons directly (e.g., through transcriptional analysis of BIII-tub positive neurons, immunophenotyping of neurons to quantify specific markers that are representative of the reported signature, etc.).

In order to support the authors' conclusions about gene changes over time in Figure 3, key genes from the RNA-seq dataset should be validated by qPCR with error bars. Specifically, showing changes in key neuro, muscle and fibroblast genes over time; key neuronal genes at later time-points that corroborate the more mature phenotype implied from the Allen brain comparison in Figure 3H; glutamatergic and GABAergic genes in order to conclude that they are expressed at roughly similar levels in Figure 3D.

The differences between NC and NC+ZPAK implied in Figures 3G and 3H seem somewhat at odds with the modest transcriptional changes reported, i.e., \"NC-ZPAK iNs possess a transcriptional profile more closely resembling that of mature neurons and that the original fibroblast transcriptional program, as well as other non-neuronal directions, were substantially reduced or absent.\" But, the first paragraph of the subsection "ZPAK induces a defined neuronal transcription that more closely relates to the adult brain transcriptome than NC alone" indicates only 143 genes were significantly differentially expressed between NC and NC+ZPAK pooling all differences across days 5, 10, 15 and 20. How do the authors integrate these two pieces of data?

The authors should also include the number of differentially expressed genes for each time-point and the full list of 143 DEGs, as supplementary figures. Since this is a small/important gene set for this study, it should be readily accessible.

Does the transcript data support the mechanistic data in Figures 4-5? Is there transcriptional evidence to support the signaling pathways induced by ZPAK over the course of conversion? (if so, again, specific gene changes should be validated from the RNA-seq). Upon activation of these signaling pathways, and dramatic differences in neurite complexity shown in Figures 4E-F, again one might expect to see more differentially expressed genes between NC and NC-ZPAK.

3\) Usefulness of the new protocol.

The authors are correct to point out that efficiency matters for investigators trying to produce cultures enriched in neurons and for those trying to make large numbers of neurons for proteomic or screening applications. However, by way of comparison, direct differentiation from iPSCs involves generating neurons from pluripotent cells that can be grown in virtually unlimited numbers. In the case of the current method, the numbers of neurons that can be produced from fibroblasts is the product of the number of fibroblasts that can be generated from each patient sample X the efficiency of differentiation. The authors have shown that the efficiency of their method is better, but how well does the method work in fibroblasts that have been passaged sufficiently to give rise to the billions of neurons that may be required? The lines used in this work were already passaged \>10 times, which is promising. However, the authors should demonstrate the process will continue to work on these fibroblast lines, especially those derived from older donors, that are passaged sufficiently to produce the requisite large numbers of neurons.
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Author response

> Essential revisions:
>
> 1\) Analyzing effects of treatment with single compounds and with ZPAK.
>
> Can the authors clarify:
>
> • Which fibroblast line(s) were used for the analyses in Figure 2 and subsequent figures?

We appreciate the reviewers' comment and agree that the cell lines used for each figure should be presented more clearly. We have revised our figure legends and added a summary in Figure 1---figure supplement 2, showing which line was for used for which experiment.

> • Whether they tested multiple inhibitors and activators of the same pathways to generate the data for Figure 1. If they tested multiple, did they all work to some degree or were the results more mixed?

Based on the pathways identified by the RNA-Seq IPA analysis presented in Figure 2B, we selected and tested a pair of molecules (one inhibitor and one activator) for each pathway. A total of 20 small molecules were tested and details on target, screening concentration, effect on iN, and reference are given in the revised Figure 2---figure supplement 2.

While we did not test multiple small molecules targeting the same pathway component, our strategy revealed that, for the selected four beneficial molecules, the 'opposite' compound of the pair always showed a strong negative, or no effect, on iN conversion. We have revised our wording to make this strategy clearer in the revised manuscript (subsection "Time based RNAseq identifies signaling pathways directing iN conversion").

> • How well ZPAK works across the different patient lines?

We agree that the consistency of ZPAK in improving direct conversion across many cell lines is a central and very important point. All presented data regarding ZPAK efficiency in our original manuscript were based on at least three individual fibroblast lines, and we see a consistent increase in conversion efficiency for all lines. To further strengthen this important point, we added new data showing the percentage of PSA-NCAM-positive cells following NK and NK^+^ZPAK conversion of all 10 lines used in the manuscript. The data were added to the new Figure 2---figure supplement 3.

> • If they compared the effects of ZPAK to those of the individual compounds based on testing single compound concentrations? Were the concentrations chosen from prior literature or from dose-response experiments that they performed? In either case, additional data to ensure that even single compounds at more optimal concentrations wouldn\'t have comparable effects to those of ZPAK should be included.

We thank the reviewers for their comment and agree that reporting the optimal concentration of the ZPAK cocktail is important to maximize the conversion benefit of this protocol. Indeed, for our initial screen of the individual compounds, we used concentrations based on literature (typically targeting a 2x EC50 concentration, also see Figure 2---figure supplement 2). However, when the four ZPAK components were combined, we observed slightly adverse effects. We therefore optimized the concentrations for the final ZPAK cocktail accordingly, yielding our 'final' ZPAK concentrations (1/4^th^ of full concentrations). For the revised manuscript, we have added new data, presented as Figure 2---figure supplement 4, to make this point clearer. We now show that (A) our final ZPAK cocktail produced more PSA-NCAM-positive iN cells than the 'full' or half concentrations; (B) the final ZPAK cocktail is superior to any individual compounds in various concentrations, and (C-D) neuronal morphologies and neuronal marker expression are optimal in the final ZPAK cocktail compared to the full and half concentrations. Further, to increase clarity, we noted the concentrations used in the figure legends when appropriate.

> 2\) Understanding the effects of small molecule signaling modulators.

Reviewer 2:

> Following NC+ZAPK treatment and Ngn2/Ascl1 expression, the fibroblasts adopt a mixed neuronal phenotype as assessed on a molecular level (Figure 3D). Are any of the neuronal branches adopted with higher frequency? Is there a change when switching from NC to NC+ZAPK? Did the authors check for this via immunofluorescence or electrophysiology?

We thank the reviewer for their comment and agree that it is important to understand if there is a difference in neuronal subtype fate commitment during conversion induced by ZPAK. Although we saw no significant differences in lineage-specifying mRNAs between NC and NC+ZPAK regarding glutamatergic versus GABAergic fate in our original manuscript, we have now extended Figure 3D towards cholinergic, dopaminergic, and serotonergic neuron-specific gene expression. Also here, we did not observe any indication of differential subtype determination between NC and NC+ZPAK.

In this new analysis, we did not observe clear differences between NC and ZPAK regarding subtype-specific gene expression. However, the levels of dopaminergic and serotonergic marker genes showed a more mixed pattern at D20 between the individual cell lines, which can likely be attributed to their low levels of expression.

Thus, to further verify stable subtype commitment and to confirm the very low levels of monoaminergic neurons in our cultures, we performed immunocytochemistry using neuronal subtype-specific antibodies against GABA, vGlut1, ChAT, TH, and 5-HT to test for GABAergic, glutamatergic, cholinergic, dopaminergic, and serotonergic, respectively. These new data were added as Figure 3---figure supplement 2.

Quantifications of immunofluorescence stainings of D20 NC and NC+ZPAK iNs revealed a clear bias towards glutamatergic neurons and a smaller population of GABAergic neurons, with \~75% of NeuN+ cells staining positive for vGlut1, and \~25% of NeuN+ cells staining positive for GABA. We observed \<5% of cells staining positive for markers of cholinergic, dopaminergic, or serotonergic neurons. These results are consistent with previous data (Mertens et al., 2015, Vadodaria et al., 2016), the transgenes used to reprogram in the UNA construct (Berniger et al., 2007; Heinrich et al., 2010), and with the RNA-Seq data presented in Figure 3D.

> The authors mention the alternative myogenic fate (as induced by Ascl1 alone in murine fibroblasts (Treutlein et al., 2016) being more highly expressed in the NC condition as compared to NC+ZPAK. Could they confirm this via staining?

We thank the reviewer for this spot-on suggestion, and we have included immunofluorescence stainings and quantifications of the myogenic marker Myh3 on D20 iNs derived in NC and NC+ZPAK that verify the suspected loss in myogenic fate through ZPAK. These new data were added to the supplement as Figure 3---figure supplement 4.

> In Figure 4C the authors show that AZ-treated cells went through significantly fewer divisions. Was cell division assessed in NC+ZAPK versus NC? In Figure 4E it looks like there are more cells in NC+ZAPK.

As described in the Materials and methods (subsection "Direct Conversion of Human Fibroblasts into iNs"), fibroblasts are pooled into high densities that on their own result in contact inhibition; only after 24h did we change to conversion media with dox, further blocking cell cycles. Thus, differences in de facto proliferation after plating are not expected to significantly influence final iN yields and densities, whereas conversion efficiency does. The observed proliferation-blocking effect of AZ, which is further accompanied by a loss of total STAT3, most likely increased conversion efficiency by promoting a postmitotic G0-like state, and thereby made the cells more amenable to adopting a neuronal identity. This explanation is consistent with previous reports of AZ960 limiting division of T cells and the known role of STAT3 in mediating cell growth and proliferation in many cell types (Yang et al., 2010; Sherry et al., 2009; Corvinus et al., 2005).

Thus, while in the representative image in Figure 4F there appear to be more cells, this observation is a direct result of more cells making it into the neuronal state with complex morphologies. Non-neuronal cells have not been traced and reconstructed and are thus not visible in this image. Instead, we feel that Figure 2D better demonstrates the described phenomenon, as it also shows similar DAPI densities, whereas more of these cells converted into βIII-tubulin-positive neurons. To further verify that not only AZ, but also ZPAK promotes a postmitotic state, we have added new CFSE experimental data that include ZPAK, and we have extended Figure 4 accordingly (see Figure 4C).

> Reviewer 3 (reviewer 1 had similar questions to those described clearly below):
>
> Comparing NC and NC+ZPAK in Figure 3, it appears the authors used bulk fibroblasts undergoing iN conversion at days 5, 10, 15 and 20. However, given the boost in conversion efficiency with ZPAK (Figures 2D-H), could the fact that there are more neurons and fewer fibroblasts in the NC+ZPAK conversion condition compared to the NC condition account for the increased \'adult / defined\' neuronal signature? Can the authors rule out a change in cell ratios and ability to detect small transcript changes in a sub-population rather than changes to the neuron population specifically? In order to conclude that NC+ZPAK not only improves efficiency of conversion but also generates neurons that are more \'human brain-like\' the authors need to compare NC neurons to NC+ZKAK neurons directly (e.g., through transcriptional analysis of BIII-tub positive neurons, immunophenotyping of neurons to quantify specific markers that are representative of the reported signature, etc.).

This a very good point and a rather complex one to answer experimentally in its entirety. First, our functional data on morphological complexity, cytoskeletal dynamics, and mitochondrial membrane potential are all *'specific markers' ...' representative of the reported signature'*. These results are indicative of '*better neurons'*, rather than merely '*more neurons'*. However, we still cannot rule out that a change in cell ratios (more neurons) underlies the observed transcriptome changes at least partially.

To provide further evidence and perform a direct comparison between NC and NC+ZPK iNs, we analyzed neural activity in four separate cell lines using live Ca^2+^ imaging (the new Figure 3---figure supplement 6). Briefly, cells were transduced with lentiviral particles for synapsin dsred and GCAMP5G and underwent live calcium imaging on a spinning disk confocal (A). Panel B illustrates that overall, cells reprogrammed in NC+ZPAK had more spontaneous calcium events than those in NC alone, and that the most active cells observed were iNs reprogrammed in NC+ZPAK. When comparing the activity of all cells studied in this experiment (n=160), we observed a significant increase in the number of calcium transients produced by iNs converted in NC+ZPAK (panel C). As calcium transients have been established as a reliable readout of neural activity in vitro, this direct comparison between NC and NC+ZPAK iNs provides further evidence that ZPAK is producing a more mature and defined neuronal state (Rosenberg and Spitzer, 2011).

> In order to support the authors' conclusions about gene changes over time in Figure 3, key genes from the RNA-seq dataset should be validated by qPCR with error bars. Specifically, showing changes in key neuro, muscle and fibroblast genes over time; key neuronal genes at later time-points that corroborate the more mature phenotype implied from the Allen brain comparison in Figure 3H; glutamatergic and GABAergic genes in order to conclude that they are expressed at roughly similar levels in Figure 3D.

We have performed qPCR validation of selected key genes to verify their differential expression over time or at day 20 in NC and NC+ZPAK. The new data were added as Figure 3---figure supplement 5. SYBR green qPCR on genes highlighted in Figure 3F showed similar patterns, as identified by RNAseq, which is consistent with our observations of decreased proliferation, suppression of myogenic genes, and improved neuronal maturity and differentiation as a result of ZPAK.

Additionally, as stated above in the our first answer to reviewer \#1, neuronal subtype specification in NC and NC-ZPAK was validated by extending Figure 3D towards rarer subtypes and by testing the immunofluorescence of subtype markers GABA, vGlut1, ChAT, TH, and TPH2.

> The differences between NC and NC+ZPAK implied in Figures 3G and 3H seem somewhat at odds with the modest transcriptional changes reported, i.e., \"NC-ZPAK iNs possess a transcriptional profile more closely resembling that of mature neurons and that the original fibroblast transcriptional program, as well as other non-neuronal directions, were substantially reduced or absent.\" But, the first paragraph of the subsection "ZPAK induces a defined neuronal transcription that more closely relates to the adult brain transcriptome than NC alone" indicates only 143 genes were significantly differentially expressed between NC and NC+ZPAK pooling all differences across days 5, 10, 15 and 20. How do the authors integrate these two pieces of data?

To determine DE genes, we applied p-value adjusted for multiple testing by the Benjamini-Hochberg method, and we set a false discovery rate cutoff at 0.05 (padj \< 0.05), yielding 143 DE genes. However, although the list of significantly differentially expressed individual genes is not very long, when assessing populations of genes via both gene ontology analysis (Figure 3G) and RRHO (Figure 3H), we observed that classes of neuronal genes were significantly more likely to be upregulated in NC+ZPAK than NC, even when the individual genes themselves weren't significantly differentially expressed. While this strategy is based on a significance cutoff and thus meets a comparatively high standard (that likely produces very few false-positive DE genes), we expect that, by limiting ourselves to this method, we missed many transcriptome changes. For the revised manuscript, we provide an additional strategy to challenge our view that ZPAK significantly improved the neuronal transcriptomes and that the 143 genes likely underestimated these differences.

We first selected pre-defined gene sets from databases such as the GO and KEGG and next plotted the mean and median fold change in NC versus NC-ZPAK of all genes per GO/KEGG gene set. While no statistical cutoff is provided, this type of analysis shows general expression changes of pre-defined and validated functional gene sets between NC and NC+ZPAK. For example, without applying any pre-filtering, several gene sets such as Neuron Differentiation, Neurite Development or Axon Guidance (GO terms) showed an upregulation in NC+ZPAK both when assessing the mean and median expression changes. These data were added as Figure 3---figure supplement 3.

> The authors should also include the number of differentially expressed genes for each time-point and the full list of 143 DEGs, as supplementary figures. Since this is a small/important gene set for this study, it should be readily accessible.

We agree that the list of significantly differentially expressed genes at each time point should be included in an easily accessible manner. We thus included a list of all DE genes in a table as part of the supplementary information as Figure 3---source data 1.

> Does the transcript data support the mechanistic data in Figures 4-5? Is there transcriptional evidence to support the signaling pathways induced by ZPAK over the course of conversion? (if so, again, specific gene changes should be validated from the RNA-seq). Upon activation of these signaling pathways, and dramatic differences in neurite complexity shown in Figures 4E-F, again one might expect to see more differentially expressed genes between NC and NC-ZPAK.

As the reviewer suggests, there is encouraging but modest transcriptional evidence supporting the mechanistic data in Figure 4, with the Log2 fold change trending in the direction of the changes reported, but these differences in transcript levels aren't significant when controlled for multiple observations as is necessary with RNA-Seq analysis. We thus agree that the list of significantly differentially expressed genes between NC and NC+ZPAK, with 143 genes at day 20, appears relatively small at first sight. As discussed above, however, we assume that the strict significance cutoff, the sampling from only three fibroblast donors (which for timeline RNA-Seq is already quite work- and cost-intensive), and the fact that bulk RNA was assessed might produce many false-negative genes. For the revised manuscript, we attempted to broaden the view on the transcriptome changes. For example, we show that gene sets that directly relate to the results presented in Figure 4E-F, such as Axon Guidance and Neurite Development, are generally upregulated in ZPAK (see our fourth answer to reviewer \#3). In addition to the differences in neurite complexity, we have also observed significantly increased neural activity as assessed by live cell calcium imaging (see our first answer to reviewer \#3). Thus, we reason that the accumulated impact of transcriptional bias towards neuronal fate induced by ZPAK results in iNs with a more defined and mature neuronal phenotype.

> 3\) Usefulness of the new protocol.
>
> The authors are correct to point out that efficiency matters for investigators trying to produce cultures enriched in neurons and for those trying to make large numbers of neurons for proteomic or screening applications. However, by way of comparison, direct differentiation from iPSCs involves generating neurons from pluripotent cells that can be grown in virtually unlimited numbers. In the case of the current method, the numbers of neurons that can be produced from fibroblasts is the product of the number of fibroblasts that can be generated from each patient sample X the efficiency of differentiation. The authors have shown that the efficiency of their method is better, but how well does the method work in fibroblasts that have been passaged sufficiently to give rise to the billions of neurons that may be required? The lines used in this work were already passaged \>10 times, which is promising. However, the authors should demonstrate the process will continue to work on these fibroblast lines, especially those derived from older donors, that are passaged sufficiently to produce the requisite large numbers of neurons.

The ability to make large numbers of iNs is indeed important for future application of this technology, and the reviewer is correct to highlight this significant goal of the improved protocol. As the fibroblasts are the only cells in this protocol that can be expanded and passaged to produce large numbers of cells, the iN approach from non-transformed fibroblasts will never yield the cell numbers that iPSC can deliver. Here, the limitation is the fibroblasts and not the conversion efficiency, and the scope of this manuscript is improving iN conversion, not extending fibroblast passages and proliferation speed, which probably results in detrimental effects on the beneficial aspects of the iN technology, such as age preservation.

However, to get the best from the fibroblasts as a cell source, we sought to verify that iNs can be obtained from highly passaged (\>30) fibroblasts. To this end, we produced 4 lines with \>30 passages to test for direct conversion with UNA and NC+ZPAK. We verified that these high passage cells were approaching replicative senescence by SA-B-Gal staining. First, we observed that the overall efficiency was reduced in both conditions when compared to early passages, which was expected based reports of senescence-limiting iN conversion (Sun et al., Nat Commun 2014). However, we found that NC+ZPAK still produced a significantly increased yield of iNs compared to NC alone also from late passage fibroblasts. We have included these data in Figure 5---figure supplement 1.
